14-3-9　ⓔ文献

  1. Jennette JC, Falk RJ, et al: 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum, 2013; 65: 1–11.

  2. Suzuki H, Kiryluk K, et al: The pathophysiology of IgA nephropathy. J Am Soc Nephrol, 2011; 22: 1795–1803.

  3. Zhao N, Hou P, et al: The level of galactose–deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int, 2012; 82: 790–796.

  4. Berthoux F, Suzuki H, et al: Autoantibodies targeting galactose–deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol, 2012; 23: 1579–1587.

  5. Berthelot L, Robert T, et al: Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes. Kidney Int, 2015; 88: 815–822.

  6. Suzuki Y, Tomino Y: Potential immunopathogenic role of the mucosa–bone marrow axis in IgA nephropathy: insights from animal models. Semin Nephrol, 2008; 28: 66–77.

  7. Suzuki H, Suzuki Y, et al: Toll–like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol, 2008; 19: 2384–2395.

  8. Makita Y, Suzuki H, et al: TLR9 activation induces aberrant IgA glycosylation via APRIL–and IL–6–mediated pathways in IgA nephropathy. Kidney Int, 2020; 97: 340–349.

  9. Kiryluk K, Li Y, et al: Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet, 2012; 8: e1002765.

  10. Johnson RJ, Hurtado A, et al: Hypothesis: dysregulation of immunologic balance resulting from hygiene and socioeconomic factors may influence the epidemiology and cause of glomerulonephritis worldwide. Am J Kidney Dis, 2003; 42: 575–581.

  11. Yokoyama H, Sugiyama H, et al: Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J–RBR). Clin Exp Nephrol, 2012; 16: 903–920.

  12. Komatsu H, Fujimoto S, et al: Clinical manifestations of Henoch–Schönlein purpura nephritis and IgA nephropathy: comparative analysis of data from the Japan Renal Biopsy Registry (J–RBR). Clin Exp Nephrol, 2016; 20: 552–560.

  13. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society et al: The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int, 2009; 76: 546–556.

  14. Mills JA, Michel BA, et al: The American College of Rheumatology 1990 criteria for the classification of Henoch–Schönlein purpura. Arthritis Rheum, 1990; 33: 1114–1121.

  15. Counahan R, Winterborn MH, et al: Prognosis of Henoch–Schonlein nephritis in children. BMJ, 1977; 2: 11–14.

  16. Ruperto N, Ozen S, et al: EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. Ann Rheum Dis, 2010; 69: 790–797.

  17. Ozen S, Pistorio A, et al: EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis, 2010; 69: 798–806.

  18. Maeda A, Gohda T, et al: Significance of serum IgA levels and serum IgA/C3 ratio in diagnostic analysis of patients with IgA nephropathy. J Clin Lab Anal, 2003; 17: 73–76.

  19. Komatsu H, Fujimoto S, et al: Relationship between serum IgA/C3 ratio and progression of IgA nephropathy. Intern Med, 2004; 43: 1023–1028.

  20. Kawasaki Y, Maeda R, et al: Serum IgA/C3 and glomerular C3 staining predict severity of IgA nephropathy. Pediatr Int, 2018; 60: 162–167.

  21. Yanagawa H, Suzuki H, et al: A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLoS One, 2014; 9: e98081.

  22. Yasutake J, Suzuki Y, et al: Novel lectin–independent approach to detect galactose–deficient IgA1 in IgA nephropathy. Nephrol Dial Transplant, 2015; 30: 1315–1321.

  23. Suzuki H, Yasutake J, et al: IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose–deficient IgA1–oriented pathogenesis. Kidney Int, 2018; 93: 700–705.

  24. Matsuzaki K, Suzuki Y, et al: Nationwide survey on current treatments for IgA nephropathy in Japan. Clin Exp Nephrol, 2013; 17: 827–833.

  25. Hirano K, Matsuzaki K, et al: Association Between Tonsillectomy and Outcomes in Patients With Immunoglobulin A Nephropathy. JAMA Netw Open, 2019; 2: e194772.